

## **Repro-Med Receives CE Approval for its FREEDOM60 Syringe Infusion Pump**

Chester, N.Y. - October 19, 2002 - Repro-Med Systems, Inc. (OTC Bulletin Board: REPR.OB) will be attending the Medica Trade Show in Dusseldorf with its now CE approved FREEDOM60 Syringe Infusion System enabling sales throughout Europe. The FREEDOM60 is a low cost, mechanically driven, accurate syringe infusion pump which utilizes conventional 60cc syringes. The FREEDOM60 is suitable for all medications which are compatible for use in a 60cc syringe which includes virtually all antibiotics, heart medications, chemotherapy, pain medication and specialty drugs such as Desferal for Thalissemia. Currently the FREEDOM60 is used in the United States for portable ambulatory patients in home care. Due to its performance, low-cost and the benefit of not having to rely on electric mains or batteries, the FREEDOM60 is also attractive to hospitals and clinics for reliable, safe intravenous delivery.

“This approval opens up the entire European market to our innovative infusion system” commented Andy Sealfon, Repro-Med’s president. “This market has tremendous potential and the FREEDOM60’s performance, portability, ease of use, safety, and attractive operational cost will be of great benefit”, he added.

The FREEDOM60 is a constant pressure pump using a safe .9 bar pressure and specific dedicated tubing sets to achieve flow rates of 0,5ml/hr to 180ml/hr. In addition to the basic pump, the Company has also made available the FREEDOM60-FM which contains a flow monitor (occlusion alarm) which signals when the infusion has halted or ended and makes the system applicable to situations requiring more monitoring such as pediatric use. The Flow Monitor actually measures the flow of fluid, thus eliminating the annoyance of false alarms so common in other systems. The Company is currently conducting clinical trials in Europe to tailor the FREEDOM60 for applications specific to the European market.

### About Repro-Med

Repro-Med Systems, Inc. engages in the design and manufacture of medical devices for medical respiratory products and infusion therapy worldwide. Repro-Med manufactures medical devices for a variety of markets including emergency-care, hospital, and home-care. The Company’s primary products are RES-Q-VAC and FREEDOM 60.

RES-Q-VAC is currently the market leader for portable suction instruments, providing a complete suction system designed to remove fluids from a patient's airway. As the RES-Q-VAC consists of a hand-held, human powered portable suction pump, it provides its benefits in many markets, being particularly effective in emergency settings. The proprietary design and disposable features of the RES-Q-VAC eliminate the risk of contaminating the health care provider when suctioning a patient or during post treatment cleanup. The product is particularly suited for emergency providers and vehicles, hospitals and as backup support for powered suction systems.

The FREEDOM60 Syringe Infusion Pump provides a portable, high quality, self powered, maintenance free delivery system for ambulatory, home and hospital use, delivering precise infusion rates and uniform flow profiles that provides consistent transfer of medication. The FREEDOM60 is a versatile, easy-to-use lightweight mechanical pump providing a cost-effective alternative to expensive electronic and disposable IV administration devices and may be used to deliver a wide range of infusion products including antibiotics, pain control, chemotherapy drugs, immune globulin, desferal, cardiac drugs, among others.

## Forward Looking Statements

Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, may be forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. These statements involve risks and uncertainties that could cause actual results to differ materially from those included in forward-looking statements due to a variety of factors. More information about these factors can be found in Repro-Med's latest Annual Report filed with Securities and Exchange Commission on Form 10-KSB. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:  
Repro-Med Systems, Inc  
Gini Vidal, 800-624-9600  
[www.Repro-Med.com](http://www.Repro-Med.com)